Q2-Header_1280x350_4

Bioanalytical Services

Q2 Solutions understands that bringing a promising drug candidate to market requires a well-planned strategy that incorporates sensitive, specific, and validated assays to inform development decisions. As such, our highly trained scientists apply leading-edge technologies, automated platforms, and state-of-the-art techniques to support a wide range of bioanalytical services and ADME services.

 

From high-throughput ADME screening services and human clearance predictions to support drug metabolism and pharmacokinetics studies to drug-drug interaction testing and metabolite profiling to support clinical safety, the Q2 Solutions global network offers solutions to support every phase of drug discovery and development.

 

Our bioanalysis services include:

  • In vitro ADME screening assays and discovery and development metabolite identification services that enable rapid drug discovery ADME property optimization and regulatory filings
  • Bioanalytical liquid chromatography mass spectrometry services for the quantitative determination of small molecule drugs and macromolecule therapeutics to support pharmacokinetic (PK) testing
  • Immunoassay services, including ELISA, MSD, ECL, and neutralizing antibody assays to facilitate pharmacokinetic (PK) testing and immunogenicity testing
  • Biomarker assays using LC/MS analysis and ligand-binding assays to quantitate biomarkers in biologic matrices.

 

In addition to specific services detailed in the sections below, Q2 Solutions can provide bundled services for discovery and regulatory-phase packages to enable decision-making at each step of the development process.

Our integrated drug metabolism solutions include high-throughput screening assays, human clearance predictions, drug-drug interaction risk assessments and metabolite profiling to support clinical safety.
Q2-Header_1280x350_4

Related Thought Leaders Insights


Hybrid Assays for Protein Bioanalysis

Authors: Steve Lowes, Ph.D., Senior Director, Bioanalytical Services Barry Jones, Ph.D., Director, LC-MS Biologics and Biomarkers Hybrid assays are powerful tools for protein bioanalysis of both...

Quantitative Assays for Peptides using LC-MS

We are one of the few bioanalytical laboratories successfully employing immunoprecipitation techniques, HRMS, and multi-dimensional liquid chromatography for the quantitation of peptide and protein...

Developing Assays for Novel Drugs

Novel drugs with complex design are becoming more common to treat difficult diseases. This insight brief, authored by Michael Brown, Ph.D., Senior Director, Immunoanalytical Services and Barry Jones,...